MARKET

LRMR

LRMR

Larimar Therapeutics Inc
NASDAQ
4.160
-0.040
-0.95%
After Hours: 4.080 -0.08 -1.92% 19:34 08/07 EDT
OPEN
4.240
PREV CLOSE
4.200
HIGH
4.280
LOW
4.080
VOLUME
631.19K
TURNOVER
--
52 WEEK HIGH
6.42
52 WEEK LOW
2.715
MARKET CAP
432.15M
P/E (TTM)
-2.0936
1D
5D
1M
3M
1Y
5Y
1D
Larimar Therapeutics price target lowered to $11 from $12 at Wedbush
TipRanks · 4d ago
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11
Benzinga · 4d ago
Larimar Therapeutics: Buy Rating Reaffirmed as FDA-Backed Nomlabofusp Progress Supports Unchanged $25 Price Target
TipRanks · 4d ago
Analyst Sees Larimar as Undervalued on Nomlabofusp’s Strong Efficacy and On‑Track BLA, Reiterates Buy Rating Ahead of 2027 FA Launch
TipRanks · 4d ago
Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp
TipRanks · 4d ago
Larimar Therapeutics reports Q2 EPS (30c), consensus (38c)
TipRanks · 5d ago
Larimar reports Q2 results and nomlabofusp progress
TipRanks · 5d ago
Larimar Therapeutics GAAP EPS of -$0.30 beats by $0.09
Seeking Alpha · 5d ago
More
About LRMR
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

Webull offers Larimar Therapeutics Inc stock information, including NASDAQ: LRMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LRMR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LRMR stock methods without spending real money on the virtual paper trading platform.